Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epinephrine nasal spray
- Development stage
- Phase 4
- Lead developer
- ARS Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Youminsu (epinephrine nasal spray, also known as Neffy) is an intranasal formulation of epinephrine developed by ARS Pharmaceuticals and licensed to Pediatrix Therapeutics and Grand Pharma (China Grand Enterprises) for development and commercialization in Greater China. It is the first needle-free, non-injectable epinephrine product approved for the emergency treatment of Type I allergic reactions, including anaphylaxis. Epinephrine acts as a non-selective agonist of alpha- and beta-adrenergic receptors. By activating these receptors, it induces vasoconstriction (via alpha-1 receptors) to counter vasodilation and hypotension, bronchodilation (via beta-2 receptors) to relieve bronchoconstriction, and reduces mediator release from mast cells and basophils, thereby reversing the life-threatening manifestations of severe allergic reactions.
- Brand names
- EURneffyNeffyYouminsu
- Other names
- adrenaline intranasal sprayadrenaline nasal sprayepinephrineepinephrine intranasal spray优敏速
02
Targets
ADRA1 (Alpha-1 adrenergic receptor family)ADRA2 (Adrenergic alpha-2 receptor family)ADRB1 (β1)ADRB3 (β3)ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)ADRB2 (β2)
Beyond the preview
Go deeper on epinephrine nasal spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epinephrine nasal spray.